- Home
- LVO vs ABOS Comparison
LVO vs ABOS Comparison
Compare LVO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- ABOS
- Stock Information
- Founded
- LVO 2009
- ABOS 1996
- Country
- LVO United States
- ABOS United States
- Employees
- LVO N/A
- ABOS N/A
- Industry
- LVO Restaurants
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- LVO Consumer Discretionary
- ABOS Health Care
- Exchange
- LVO Nasdaq
- ABOS Nasdaq
- Market Cap
- LVO 79.4M
- ABOS 76.9M
- IPO Year
- LVO N/A
- ABOS 2021
- Fundamental
- Price
- LVO $0.64
- ABOS $0.90
- Analyst Decision
- LVO Strong Buy
- ABOS Strong Buy
- Analyst Count
- LVO 2
- ABOS 3
- Target Price
- LVO $2.75
- ABOS $7.33
- AVG Volume (30 Days)
- LVO 330.5K
- ABOS 253.0K
- Earning Date
- LVO 05-29-2025
- ABOS 05-13-2025
- Dividend Yield
- LVO N/A
- ABOS N/A
- EPS Growth
- LVO N/A
- ABOS N/A
- EPS
- LVO N/A
- ABOS N/A
- Revenue
- LVO $126,016,000.00
- ABOS N/A
- Revenue This Year
- LVO $0.69
- ABOS N/A
- Revenue Next Year
- LVO N/A
- ABOS N/A
- P/E Ratio
- LVO N/A
- ABOS N/A
- Revenue Growth
- LVO 11.43
- ABOS N/A
- 52 Week Low
- LVO $0.55
- ABOS $0.90
- 52 Week High
- LVO $1.99
- ABOS $3.92
- Technical
- Relative Strength Index (RSI)
- LVO 42.64
- ABOS 34.21
- Support Level
- LVO $0.62
- ABOS $0.95
- Resistance Level
- LVO $0.69
- ABOS $1.15
- Average True Range (ATR)
- LVO 0.07
- ABOS 0.11
- MACD
- LVO 0.00
- ABOS -0.00
- Stochastic Oscillator
- LVO 48.13
- ABOS 10.29
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.